We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FASENRA AstraZeneca Pty Ltd
Product name
FASENRA
Sponsor
Accepted date
Sep-2025
Active ingredients
benralizumab
Proposed indication
FASENRA (benralizumab) is proposed to treat people aged 12 and over who have hypereosinophilic syndrome. This treatment is for those whose condition is not caused by another illness outside the blood or bone marrow.
Application type
C (new indication)
Publication date
Sep-2025